What question did this study set out to answer?

This study aims to assess the safety, pharmacokinetics, and antiretroviral effectiveness of nevirapine for HIV-1-infected pregnant women and their newborns.

March 1, 1999AIDS

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)

View Full Paper

Ask AI

Bookmark

Authors

PMPhilippa MusokeCenters for Disease Control and Prevention LGLaura GuayRutgers, The State University of New Jersey DBDanstan BagendaUniversity of Nebraska Medical Center

Discussion

Member takes

Implication

Phase I/II trial evaluates nevirapine safety and activity in HIV-1-infected pregnant women and their infants, suggesting effective prophylaxis.

Key Points

This study aims to assess the safety, pharmacokinetics, and antiretroviral effectiveness of nevirapine for HIV-1-infected pregnant women and their newborns.
Open label phase I/II study involving 21 HIV-1-infected pregnant Ugandan women.
Nevirapine (200 mg) administered during labor; infants received either no dose or 2 mg/kg at 72 hours.
Outcomes included maternal adverse events, plasma nevirapine concentrations, and infant HIV infection status.
Nevirapine was well tolerated with no serious adverse events related to the drug.
Median maternal nevirapine concentration at delivery was 1623 ng/ml; 100% of infants exceeded 100 ng/ml at 7 days.
Infant HIV infection rates were 4.5% at birth, 14% at 6 weeks, and 19% at 6 months.

Cite This Study

Musoke et al. (1999) studied this question.

synapsesocial.com/papers/6a21c3d7fc862bbf43c00470 https://doi.org/10.1097/00002030-199903110-00006

View Full Paper

Ask AI

Bookmark

Implication

Phase I/II trial evaluates nevirapine safety and activity in HIV-1-infected pregnant women and their infants, suggesting effective prophylaxis.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)

Discussion

Member takes

Implication

Key Points

Cite This Study

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider